BridgeBio (BBIO.US) Heart Disease Therapy Acoramidis Real World Study Outperforms Competitive Pfizer (PFE.US) Drugs

The Zhitong Finance App learned that BridgeBio Pharma (BBIO.US) announced on Wednesday that its heart disease treatment acoramidis (US brand name: Attruby) performed better than Pfe.US (PFE.US) competitor drug tafamidis (US brand name Vyndamax) in a real-world study.

In November 2024, the US Food and Drug Administration (FDA) approved Attruby for the treatment of transthyroxine amyloid cardiomyopathy (ATTR-CM). It's a rare heart disease affecting 300,000 to 500,000 people worldwide, and Pfizer (PFE.US) dominates this field with Vyndamax.

BridgeBio quoted peer-reviewed data as saying that acoramidis is associated with a 34% decline in the comprehensive index of clinical deterioration events, and this decline is significant in both statistical and clinical terms. This comprehensive index includes conditions such as intensive treatment with diuretics, and increased use of diuretics is one of the early indicators of worsening heart failure.

The results of the study published in the medical journal “Cardiology and Therapy” were based on US health insurance claims data. The study subjects included 170 patients who started using acoramidis and 448 patients who started using tafamidis. The time span was December 2024 to April 2025. Follow-up of these patients continued until July 2025, with an average follow-up time of about 4.6 months. The company plans to publish more real-world data at a medical conference in the fall to further demonstrate the advantages of acoramidis over acoramidis.